OCEAN(a) Outcomes (Follow-up)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)
- Medicine
- Olpasiran
- Population
- ASCVD
- Phase
- III
- Starting year
- 2022